Literature DB >> 22614156

Prognostic value of tumor progression-related gene expression in colorectal cancer patients.

Miriam E Uhlmann1, Milka Georgieva, Martin Sill, Ulrich Linnemann, Martin R Berger.   

Abstract

PURPOSE: Colorectal cancer (CRC) is driven by genetic alterations causing its progression. Besides accepted tumor suppressor- and onco- genes, a series of genes have been identified, which contribute to transformation into a more malignant stage. We investigated whether the expression level of such genes, alone or in combination, could add to predict the prognosis of CRC patients.
METHODS: Tumor samples from 118 CRC patients were screened in a retrospective analysis by qRT-PCR for expression of the four tumor progression-associated genes osteopontin (Opn), transforming growth factor β (Tgf-β), matrix metalloproteinase-2 (Mmp-2) and cyclooxigenase-2 (Cox-2). The resulting qRT-PCR values were related to those of housekeeping genes. All patients were clustered for similar expression levels between the four genes with R statistical software using the package pvclust, which provides bootstrap agglomerative hierarchical clustering. Clusters with similar expression of the four genes were analyzed for correlation with UICC stages and survival time.
RESULTS: Expression of the four genes varied considerably within the cohort of patients. Cluster analysis of patients revealed a subgroup (n = 33) who in comparison with the other patients showed tenfold higher expression levels of all four genes (p < 0.001, respectively). However, there was no correlation between patients expressing high or low levels of these four genes and known parameters of clinical prognosis (UICC stages, survival time).
CONCLUSIONS: In conclusion, tenfold increased expression levels of Opn, Tgf-β, Mmp-2 and Cox-2 in a subset of CRC patients did not predict for a clinical outcome that is different from that of the remaining patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614156     DOI: 10.1007/s00432-012-1238-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  44 in total

1.  Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data.

Authors:  Christian Ramakers; Jan M Ruijter; Ronald H Lekanne Deprez; Antoon F M Moorman
Journal:  Neurosci Lett       Date:  2003-03-13       Impact factor: 3.046

Review 2.  Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis.

Authors:  E Fosslien
Journal:  Ann Clin Lab Sci       Date:  2001-10       Impact factor: 1.256

3.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

4.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

Review 5.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

6.  Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.

Authors:  D R Senger; C A Perruzzi
Journal:  Biochim Biophys Acta       Date:  1996-11-08

7.  Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments.

Authors:  Yu Alice Gao; Renu Agnihotri; Calvin P H Vary; Lucy Liaw
Journal:  Matrix Biol       Date:  2004-11       Impact factor: 11.583

8.  Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer.

Authors:  Katarzyna Guzinska-Ustymowicz; Andrzej Kemona
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

9.  Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

Authors:  H Sano; Y Kawahito; R L Wilder; A Hashiramoto; S Mukai; K Asai; S Kimura; H Kato; M Kondo; T Hla
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

10.  A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1.

Authors:  A Picon; L I Gold; J Wang; A Cohen; E Friedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-06       Impact factor: 4.254

View more
  6 in total

1.  The Contribution of Matrix Metalloproteinase-1 Genotypes to Hepatocellular Carcinoma Susceptibility in Taiwan.

Authors:  Yi-Liang Lai; Chi-Li Gong; Chun-Kai Fu; Te-Cheng Yueh; Chia-Wen Tsai; Wen-Shin Chang; Chieh-Lun Hsiao; Shiou-Ting Yen; Hsin-Ting Li; Long-Bin Jeng; Shou-Cheng Wang; DA-Tian Bau
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

Review 2.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

3.  Matrix metalloproteinase 2 overexpression and prognosis in colorectal cancer: a meta-analysis.

Authors:  Mumu Shi; Bo Yu; Hongguo Gao; Jingwen Mu; Changwei Ji
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

4.  MMP-1/2 and TIMP-1/2 expression levels, and the levels of collagenous and elastic fibers correlate with disease progression in a hamster model of tongue cancer.

Authors:  Haixia Fan; Wenhao Jiang; Haixia Li; Ming Fang; Yudong Xu; Jinhua Zheng
Journal:  Oncol Lett       Date:  2015-10-29       Impact factor: 2.967

5.  Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: a meta-analysis.

Authors:  Xin-Lin Chen; Zhuo-Qun Chen; Shui-Lian Zhu; Tian-Wen Liu; Yi Wen; Yi-Sheng Su; Xu-Jie Xi; Yue Hu; Lei Lian; Feng-Bin Liu
Journal:  BMC Cancer       Date:  2017-04-04       Impact factor: 4.430

6.  The impact of osteopontin on prognosis and clinicopathology of colorectal cancer patients: a systematic meta-analysis.

Authors:  Mingfei Zhao; Feng Liang; Buyi Zhang; Wei Yan; Jianmin Zhang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.